Marginal Zone Lymphoma Market

Market Overview:

The 7 major marginal zone lymphoma markets reached a value of US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.7 Billion by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2024-2034.

The marginal zone lymphoma market has been comprehensively analyzed in IMARC's new report titled "Marginal Zone Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Marginal zone lymphoma is a type of non-Hodgkin lymphoma that arises from the marginal zone B cells in the lymphoid tissue. Some of the common symptoms include painless swelling of lymph nodes, particularly in the neck, armpits, or groin, as well as various nonspecific indications, like fatigue, night sweats, unexplained weight loss, fever, etc. In a few cases, the ailment may affect extranodal sites, leading to symptoms specific to the impacted organ, such as abdominal pain, gastrointestinal bleeding, respiratory difficulties, etc. The diagnosis of marginal zone lymphoma involves a combination of clinical evaluation, imaging studies, laboratory investigations, and histopathological examination. Several diagnostic imaging tests, including computed tomography (CT) scan and positron emission tomography (PET) scan, help in evaluating the extent of disease progression and identifying affected lymph nodes as well as extranodal sites. A definitive diagnosis is made through a lymph node or tissue biopsy, followed by a histopathological examination by a pathologist, which consists of microscopic analysis, immunohistochemistry, and flow cytometry to determine the presence of lymphoma cells and classify the specific subtype of the ailment.

The rising cases of specific genetic and molecular alterations that can disrupt normal cellular processes and interfere with the regulation of signaling pathways involved in cell survival and immune responses are primarily driving the marginal zone lymphoma market. In addition to this, the escalating utilization of localized radiation therapy, which involves directing high-energy beams to the affected lymph nodes or organs, for controlling the disease and providing long-term remission is creating a positive outlook for the market. Moreover, the inflating adoption of stem cell transplantation for replacing diseased bone marrow with stem cells to allow the production of new, healthy blood cells is also bolstering the market growth. Additionally, the rising demand for antibody-drug conjugates for treating the ailment on account of their several associated benefits, including enhanced efficacy, targeted therapy, reduced systemic toxicity, etc., is acting as another significant growth-inducing factor. Apart from this, the emerging popularity of cytogenetic analysis, such as chromosomal microarray analysis (CMA), since it aids in detecting chromosomal aberrations, including translocations or deletions, that can help in providing prognostic information and differentiating the ailment from other lymphoma subtypes, is expected to drive the marginal zone lymphoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the marginal zone lymphoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for marginal zone lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the marginal zone lymphoma market in any manner.

Recent Developments:

• In May 2024, ADC Therapeutics SA revealed that preliminary data from an investigator-initiated Phase 2 clinical trial investigating ZYNLONTA (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma.

Key Highlights:

• According to the World Health Organization classification, the three distinct marginal zone lymphoma (MZL) entities with specific diagnostic criteria, behavior, and therapeutic implications occur at the following rates: extranodal MZL of mucosa-associated lymphoid tissue (MALT) in 70% of cases, splenic MZL in 10% of cases, and nodal MZL in 20% of cases.
• MZL makes up about 6% (the literature ranges from 2 to 12%) of all B-cell lymphomas.
• The most prevalent extranodal site is the stomach/gastric (GALT lymphoma), followed by the ocular/adnexal, lung, skin, and salivary gland.
• The median age of a MZL diagnosis is 67 years, with men having a slightly higher incidence.
• It is estimated that there are between 1000 and 2300 instances per year in the United States.

Drugs:

Imbruvica (Ibrutinib) is a once-daily oral medicine co-developed and commercialized by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie subsidiary. IMBRUVICA inhibits Bruton's tyrosine kinase (BTK) protein, which is required for normal and aberrant B cells, including certain cancer cells, to grow and spread. By suppressing BTK, IMBRUVICA may help transfer aberrant B cells out of their feeding surroundings and reduce their proliferation.

Loncastuximab tesirine is a CD19-specific antibody-drug conjugate (ADC). After binding to a CD19-expressing cell, loncastuximab tesirine is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to the DNA minor groove with minimal distortion, making it less detectable to DNA repair machinery. This finally leads to cell cycle arrest and tumor cell death.

Tafasitamab is a humanized Fc-modified immunotherapy that targets CD19. MorphoSys licensed Xencor, Inc.'s exclusive worldwide rights to develop and market tafasitamab in 2010. Tafasitamab contains an XmAb-engineered Fc domain that promotes B-cell lysis via apoptosis and immunological effector mechanisms such as Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the marginal zone lymphoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the marginal zone lymphoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current marginal zone lymphoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the marginal zone lymphoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the marginal zone lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the marginal zone lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of marginal zone lymphoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of marginal zone lymphoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of marginal zone lymphoma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with marginal zone lymphoma across the seven major markets?
• What is the size of the marginal zone lymphoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of marginal zone lymphoma?
• What will be the growth rate of patients across the seven major markets?
   

Marginal Zone Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for marginal zone lymphoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the marginal zone lymphoma market?
• What are the key regulatory events related to the marginal zone lymphoma market?
• What is the structure of clinical trial landscape by status related to the marginal zone lymphoma market?
• What is the structure of clinical trial landscape by phase related to the marginal zone lymphoma market?
• What is the structure of clinical trial landscape by route of administration related to the marginal zone lymphoma market?